Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) reported that subsidiary Cana Laboratories has advanced international patent application WO2025108566A1, covering its CCX0722 hydrogel weight management platform, into the U.S., Europe, Australia, and Canada.
The company now owns the CCX0722 intellectual property outright and targets major markets within a global weight management sector projected to reach $562.2 billion by 2033.
Cosmos Health (NASDAQ:COSM) reported accelerating traction for its proprietary antiseptic C-Sept PRO in leading Greek public and private hospital groups. Average sales exceeded $93,000 per month over six months, rising above $108,000 per month recently, putting annualized sales above $1.3 million at roughly 72% gross margin.
According to Cosmos Health, this creates a high-margin, recurring hospital revenue stream in Greece, with plans to expand the hospital-focused antiseptics business into additional European markets over time.
Cosmos Health (NASDAQ:COSM) signed an agreement to deploy an AI-powered call center for its subsidiary CosmoFarm, supporting order intake and routine customer communications. The multilingual platform will automate inbound and outbound calls, integrate with back-end systems, and provide real-time reporting, targeting process optimization, cost efficiencies, and improved customer experience.
This move extends Cosmos Health’s broader AI strategy, launched in April 2026, which applies AI across front-end and back-end operations. According to Cosmos Health, AI-driven optimization may reduce certain operating expenses by up to 30%, depending on the process and automation level.
Cosmos Health (NASDAQ:COSM) reported that subsidiary Cana Laboratories has built a contract manufacturing orderbook of over 25 million units across multiple EU and international partners and nine therapeutic categories. Multi-year agreements extend up to 10 years, produced at Cana’s upgraded, 54,000 sq. ft. EU-GMP, EMA-certified Athens facility.
Cosmos Health has invested about $5.5 million in facility upgrades, including a new ACG capsule-filling line. At full capacity, the contract manufacturing division is positioned to generate over $10 million in recurring annual profit, with current contracts using only part of available capacity.
Cosmos Health (NASDAQ:COSM) reported that subsidiary CosmoFarm achieved record Q2 2026 revenue of over $15 million, implying an annualized run-rate above $60 million.
CosmoFarm added 80+ pharmacies, and Cosmos Health is boosting capital expenditure for AI-driven robotic automation and facility expansion to support volume growth, efficiency and margins.
Cosmos Health (NASDAQ:COSM), via its subsidiary Cana Laboratories, signed a five-year contract manufacturing agreement with Pharmex for three dermatological products.
The deal covers approximately 2.86 million units, enhances utilization of Cana’s EU-GMP, EMA-certified facility, and targets higher-margin, recurring contract manufacturing revenue.
Cosmos Health (NASDAQ:COSM) updated its U.S. portfolio, highlighting the science-based 18 Series nutraceutical line. Four launched products with projections—Noor18, Liv18, Fort18, Cur18—target annualized U.S. revenue of over $22.7M and implied gross profit of about $17.0M at ~75% gross margins.
The 18 Series remains early stage; the company aims for 18 products and views the U.S. platform as a long-term revenue and profitability pillar.
Cosmos Health (NASDAQ:COSM) announced that its subsidiary Cana Laboratories received new contract manufacturing orders from Nassington and Verisfield totaling 253,657 units.
The contracts cover multiple medicines and pharmaceutical products, supporting Cosmos Health's vertically integrated, diversified manufacturing business and reinforcing relationships with established pharmaceutical partners.
Cosmos Health (NASDAQ:COSM) reported over $1.5 million in combined annualized sales for its C-Scrub and C-Sept antiseptic brands across the UK and Greece, with gross margins above 70%.
The company targets 2028 revenue of $7.4 million and gross profit of $5.3 million via EU expansion and animal healthcare.
Cosmos Health (NASDAQ:COSM) signed a non-binding LOI to acquire 100% of Doc Pharma S.A., a GMP pharmaceutical manufacturer. Doc Pharma has an approximately $24 million asset base, $6.7 million three-year average annual revenue and $3.2 million gross profit.
The deal is expected to be accretive, enhancing assets, margins, profitability, cash flow, production capacity, product portfolio, and R&D. It is a related-party transaction, subject to independent review, PCAOB audit, shareholder approval, final due diligence, and may not close.